Patient Guide: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 15 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04064827
Status: 🟢 Enrolling Now
Condition: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Phase: PHASE3

Where You Can Participate

This study is available at 15 locations across the country.

Top locations include:
  • • Little Rock, Arkansas
  • • Redwood City, California
  • • Washington, District of Columbia
  • • And 12 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) - Join Clinical Trial NCTNCT04064827

How to Join This Clinical Trial - NCTNCT04064827

Learn how to participate in this PHASE3 trial studying an investigational therapy for Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT). This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04064827 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 15 locations. Find a study site near you:

Clinical Research Site

Little Rock, Arkansas 72202 - United States

Status: COMPLETED

Clinical Research Site

Redwood City, California 94063 - United States

Status: RECRUITING

Clinical Research Site

Washington, District of Columbia 20010-2916 - United States

Status: RECRUITING

Clinical Research Site

Miami, Florida 33136-1005 - United States

Status: RECRUITING

Clinical Research Site

Miami, Florida 33155-3009 - United States

Status: COMPLETED

Clinical Research Site

Atlanta, Georgia 30322-1014 - United States

Status: COMPLETED

Clinical Research Site

Augusta, Georgia 30912-0004 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02115 - United States

Status: RECRUITING

Clinical Research Site

Charlotte, North Carolina 28203-5866 - United States

Status: COMPLETED

Clinical Research Site

Winston Salem, North Carolina 27157-0001 - United States

Status: RECRUITING

And 5 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT):

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships